112 related articles for article (PubMed ID: 23133935)
1. [Proteasome oncology: pioneer a new field in drug development].
Mita N; Murata S
Nihon Rinsho; 2012 Apr; 70 Suppl 2():96-102. PubMed ID: 23133935
[No Abstract] [Full Text] [Related]
2. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
Driscoll JJ; Chowdhury RD
Cancer Lett; 2012 Dec; 325(2):147-54. PubMed ID: 22781397
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
4. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
6. Molecule of the month. Bortezomib.
Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
[No Abstract] [Full Text] [Related]
7. [Proteasome inhibitors for multiple myeloma].
Yano H; Iida S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
[No Abstract] [Full Text] [Related]
8. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
9. [Proteasome inhibitors--new option in the treatment of tumor diseases].
Spicka I; Klener P
Cas Lek Cesk; 2004; 143(10):701-4. PubMed ID: 15584622
[TBL] [Abstract][Full Text] [Related]
10. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
11. The proteasome--an emerging therapeutic target in cancer.
Mitchell BS
N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
[No Abstract] [Full Text] [Related]
12. New oncology strategy: molecular targeting of cancer cells.
Capriotti T
Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169
[No Abstract] [Full Text] [Related]
13. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
[No Abstract] [Full Text] [Related]
14. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
15. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
16. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
17. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
18. The proteasome: a new target for novel drug therapies.
Elliott PJ; Ross JS
Am J Clin Pathol; 2001 Nov; 116(5):637-46. PubMed ID: 11710679
[TBL] [Abstract][Full Text] [Related]
19. Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
Garfield DH; Cadranel JL
Lung Cancer; 2007 Aug; 57(2):249-50. PubMed ID: 17599646
[No Abstract] [Full Text] [Related]
20. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]